Virucidal Therapeutics
Building on proven rHDL production technology, we are developing virucidal therapies designed to combat enveloped viruses such as COVID-19, influenza, and mpox.
Overcoming the Biggest Challenge in Antiviral Development : Resistance
Using virus-recognized receptors, our approach ensures consistent efficacy against mutations, tackling resistance through a virus-killing mechanism.
Safe, Human-Derived Materials
Developed with rHDL, known as "good cholesterol" and other human-derived substances, and our therapeutics ensures high safety and virus-specific action, minimizing cytotoxicity concerns.
We are developing innovative, customized antiviral therapies that leverage "good cholesterol" rHDL to destroy a variety of enveloped viruses.
What is the first-in-class virucidal rHDL(VH)?
Structure of Virucidal rHDL(VH)
rHDL Platform as a Virucidal Therapy
Mechanism of Action of Virucidal rHDL: Harnessing the Virus’s Own Infection Pathway
-
In the body, virucidal rHDL encounters and attaches to the virus
-
The virus, now bound with virucidal rHDL, enters the host cell and forms an endosome
-
As the endosome's pH decreases, the virus fuses with the phospholipid component of virucidal rHDL
-
This fusion releases the viral nucleic acids into the endosome, where they are subsequently degraded by lysozymes and other enzymes
First-in-class variant-resistant virucidal therapeutics
World's First Virucidal Platform Technology
-
Adaptable to various enveloped viruses through viral receptor modifications
-
Customizable design with diverse structures and configurations tailored to specific goals
Safety of Human-Derived Cholesterol Carrier
-
Proven rHDL production technology with established stability
-
Composed entirely of human-derived materials for exceptional safety
Reduced Risk of Resistance
-
First-ever treatment with a virucidal mechanism
-
Mechanism leverages the virus’s own infection process
Research Achievements
0000-00-00
Title
Author
Paper
0000-00-00
Title
Author
Paper
0000-00-00
Title